Pharmacotherapy of ulcerative colitis – current status and emerging trends

References

1. Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol 2015;12:205–17.10.1038/nrgastro.2015.34Search in Google Scholar PubMed

2. Da Silva BC, Lyra AC, Rocha R, Santana GO. Epidemiology, demographic characteristics and prognostic predictors of ulcerative colitis. World J Gastroenterol 2014;20:9458–67.10.3748/wjg.v20.i28.9458Search in Google Scholar PubMed PubMed Central

3. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012;142:46–54.10.1053/j.gastro.2011.10.001Search in Google Scholar PubMed

4. Sood A, Midha V, Sood N, Bhatia AS, Avasthi G. Incidence and prevalence of ulcerative colitis in Punjab, North India. Gut 2003;52:1587–90.10.1136/gut.52.11.1587Search in Google Scholar PubMed PubMed Central

5. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010;105:501–23.10.1038/ajg.2009.727Search in Google Scholar PubMed

6. Satsangi J, Silverberg MS, Vermeire S, Colombel J. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006;55:749–53.10.1136/gut.2005.082909Search in Google Scholar PubMed PubMed Central

7. Strong SA. Management of acute colitis and toxic megacolon. Clin Colon Rectal Surg 2010;23:274–84.10.1055/s-0030-1268254Search in Google Scholar PubMed PubMed Central

8. Veloso FT, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol 1996;23:29–34.10.1097/00004836-199607000-00009Search in Google Scholar PubMed

9. Evans PE, Pardi DS. Extraintestinal manifestations of inflammatory bowel disease: focus on the musculoskeletal, dermatologic, and ocular manifestations. MedGenMed 2007;9:55.Search in Google Scholar

10. Knights D, Lassen KG, Xavier RJ. Advances in inflammatory bowel disease pathogenesis: linking host genetics and the microbiome. Gut 2013;62:1505–10.10.1136/gutjnl-2012-303954Search in Google Scholar PubMed PubMed Central

11. Elson CO, Cong Y. Host-microbiota interactions in inflammatory bowel disease. Gut Microbes 2012;3:332–44.10.4161/gmic.20228Search in Google Scholar PubMed PubMed Central

12. Sartor RB. Mechanisms of disease: pathogenesis of Crohn’s disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2006;3:390–407.10.1038/ncpgasthep0528Search in Google Scholar

13. Heller F, Florian P, Bojarski C, Richter J, Christ M, Hillenbrand B, et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterol 2005;129:550–64.10.1016/j.gastro.2005.05.002Search in Google Scholar

14. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet 2007;369:1627–40.10.1016/S0140-6736(07)60750-8Search in Google Scholar

15. Ebert EC, Geng X, Lin J, Das KM. Autoantibodies against human tropomyosin isoform 5 in ulcerative colitis destroys colonic epithelial cells through antibody and complement-mediated lysis. Cell Immunol 2006;244:43–9.10.1016/j.cellimm.2007.02.004Search in Google Scholar

16. Wen Z, Fiocchi C. Inflammatory bowel disease: autoimmune or immune-mediated pathogenesis? Clin Dev Immunol 2004;11:195–204.10.1080/17402520400004201Search in Google Scholar

17. Cohavy O, Bruckner D, Gordon LK, Misra R, Wei B, Eggena ME, et al. Colonic bacteria express an ulcerative colitis pANCA-related protein epitope. Infect Immun 2000;68:1542–8.10.1128/IAI.68.3.1542-1548.2000Search in Google Scholar

18. Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet 2012;380:1606–19.10.1016/S0140-6736(12)60150-0Search in Google Scholar

19. Fernandez-Becker NQ, Moss AC. Improving delivery of aminosalicylates in ulcerative colitis: effect on patient outcomes. Drugs 2008;68:1089–103.10.2165/00003495-200868080-00006Search in Google Scholar PubMed

20. Cohen RD, Woseth DM, Thisted RA, Hanauer SB. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 2000;95:1263–76.10.1111/j.1572-0241.2000.01940.xSearch in Google Scholar PubMed

21. Campieri M, De Franchis R, Bianchi Porro G, Ranzi T, Brunetti G, Barbara L. Mesalazine (5-aminosalicylic acid) suppositories in the treatment of ulcerative proctitis or distal proctosigmoiditis. A randomized controlled trial. Scand J Gastroenterol 1990;25:663–8.10.3109/00365529008997590Search in Google Scholar PubMed

22. Cortot A, Maetz D, Degoutte E, Delette O, meunier P, Tan G, et al. Mesalamine foam enema versus mesalamine liquid enema in active left-sided ulcerative colitis. Am J Gastroenterol 2008;103:3106–14.10.1111/j.1572-0241.2008.02152.xSearch in Google Scholar PubMed

23. Lichtenstein GR, Kamm MA, Boddu P, Gubergrits N, Lyne A, Butler T, et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2007;5:95–102.10.1016/j.cgh.2006.10.025Search in Google Scholar PubMed

24. Prantera C, Kohn A, Campieri M, Caprilli R, Cottone M, Pallone F, et al. Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX^® with Asacol^® Aliment Pharmacol Ther 2009;30:908–18.10.1111/j.1365-2036.2009.04117.xSearch in Google Scholar PubMed

25. Chen QK, Yuan SZ, Wen ZF, Zhong YQ, Li CJ, Wu HS, et al. Characteristics and therapeutic efficacy of sulfasalazine in patients with mildly and moderately active ulcerative colitis. World J Gastroenterol 2005;11:2462–6.10.3748/wjg.v11.i16.2462Search in Google Scholar PubMed PubMed Central

26. Feurle GE, Theuer D, Velasco S, Barry BA, Wördehoff D, Sommer A, et al. Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomised double blind trial. Gut 1989;30:1354–61.10.1136/gut.30.10.1354Search in Google Scholar PubMed PubMed Central

27. Zinberg J, Molinas S, Das KM. Double-blind placebo-controlled study of olsalazine in the treatment of ulcerative colitis. Am J Gastroenterol 1990;85:562–6.Search in Google Scholar

28. Travis SP, Tysk C, de Silva HJ, Sandberg-Gertzen H, Jewell DP, Jarnerot G. Optimum dose of olsalazine for maintaining remission in ulcerative colitis. Gut 1994;35:1282–6.10.1136/gut.35.9.1282Search in Google Scholar PubMed PubMed Central

29. Kiilerich S, Ladefoged K, Rannem T, Ranlov PJ. Prophylactic effects of olsalazine v sulphasalazine during 12 months maintenance treatment of ulcerative colitis. The Danish Olsalazine Study Group. Gut 1992;33:252–5.10.1136/gut.33.2.252Search in Google Scholar PubMed PubMed Central

30. Levine DS, Riff DS, Pruitt R, Wruble L, Koval G, Sales D, et al. A randomized, double blind, dose–response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. Am J Gastroenterol 2002;97:1398–407.10.1016/S0002-9270(02)04137-0Search in Google Scholar

31. Giaffer MH, Holdsworth CD, Lennard-Jones JE, Rodrigues CA, McIntyre PB, Manjunatha S, et al. Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day. Aliment Pharmacol Ther 1992;6:479–85.10.1111/j.1365-2036.1992.tb00561.xSearch in Google Scholar PubMed

32. Ulcerative colitis | Guidance and guidelines | NICE. https://www.nice.org.uk/guidance/cg166, accessed on 12 December 2015.Search in Google Scholar

33. Murphy SJ, Mayer L, Abreu MT. Mesalamine (5-aminosalicylic acid) therapy well tolerated in a patient with aspirin hypersensitivity and ulcerative colitis. J Clin Gastroenterol 2011;45:83–4.10.1097/MCG.0b013e3181dffcb4Search in Google Scholar PubMed

34. Lichtenstein GR, Kamm MA. Review article: 5-aminosalicylate formulations for the treatment of ulcerative colitis – methods of comparing release rates and delivery of 5-aminosalicylate to the colonic mucosa. Aliment Pharmacol Ther 2008;28: 663–73.10.1111/j.1365-2036.2008.03751.xSearch in Google Scholar PubMed

35. Punchard NA, Greenfield SM, Thompson RP. Mechanism of action of 5-aminosalicylic acid. Mediators Inflamm 1992;1:151–65.10.1155/S0962935192000243Search in Google Scholar

36. Rachmilewitz D, Karmeli F, Schwartz LW, Simon PL. Effect of aminophenols (5-ASA and 4-ASA) on colonic interleukin-1 generation. Gut 1992;33:929–32.10.1136/gut.33.7.929Search in Google Scholar

37. Frieri G, Pimpo M, Galletti B, Palumbo G, Corrao G, Latella G, et al. Long-term oral plus topical mesalazine in frequently relapsing ulcerative colitis. Dig Liver Dis 2005;37:92–6.10.1016/j.dld.2004.09.017Search in Google Scholar

38. Bantel H, Berg C, Vieth M, Stolte M, Kruis W, Schulze-Osthoff K. Mesalazine inhibits activation of transcription factor NF-kappa B in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol 2000;95:3452–7.10.1016/S0002-9270(00)02153-5Search in Google Scholar

39. Rousseaux C, Lefebvre B, Dubuquoy L, Lefebvre P, Romano O, Auwerx J, et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator–activated receptor-gamma. J Exp Med 2005;201:1205–15.10.1084/jem.20041948Search in Google Scholar PubMed PubMed Central

40. Schwab M, Klotz U. Pharmacokinetic considerations in the treatment of inflammatory bowel disease. Clin Pharmacokinet 2001;40:723–51.10.2165/00003088-200140100-00003Search in Google Scholar PubMed

41. https://www.accessdata.fda.gov/scripts/cder/drugsatfda, accessed on 12 December 2015.Search in Google Scholar

42. Abreu MT. The multimatrix mesalamine formulation. Gastroenterol Hepatol 2007;3:288.Search in Google Scholar

43. Das KM, Dubin R. Clinical pharmacokinetics of sulphasalazine. Clin Pharmacokinet 1976;1:406–25.10.2165/00003088-197601060-00002Search in Google Scholar PubMed

44. Rao SS, Dundas SA, Holdsworth CD, Cann PA, Palmer KR, Corbett CL. Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double blind study. Gut 1989;30:675–9.10.1136/gut.30.5.675Search in Google Scholar PubMed PubMed Central

45. Dick AP, Grayson MJ, Carpenter RG, Petrie A. Controlled trial of sulphasalazine in the treatment of ulcerative colitis. Gut 1964;5:437–42.10.1136/gut.5.5.437Search in Google Scholar PubMed PubMed Central

46. Hanauer SB, Sandborn WJ, Kornbluth A, Katz S, Safdi M, Woogen S, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol 2005;100:2478–85.10.1111/j.1572-0241.2005.00248.xSearch in Google Scholar PubMed

47. Hanauer SB, Sandborn WJ, Dallaire C, Archambault A, Yacyshyn B, Yeh C, et al. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: the ASCEND I trial. Can J Gastroenterology 2007;21:827–34.10.1155/2007/862917Search in Google Scholar PubMed PubMed Central

48. Sandborn WJ, Regula J, Feagan BG, Belousova E, Jojic N, Lukas M, et al. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology 2009;137:1934–43.10.1053/j.gastro.2009.08.069Search in Google Scholar PubMed

49. Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012;6:991–1030.10.1016/j.crohns.2012.09.002Search in Google Scholar PubMed

50. Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011;60:571–607.10.1136/gut.2010.224154Search in Google Scholar PubMed

51. Marshall JK, Irvine EJ. Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis. Am J Gastroenterol 2000;95:1628–36.10.1111/j.1572-0241.2000.02180.xSearch in Google Scholar PubMed

52. Moss AC, Peppercorn MA. The risks and the benefits of mesalazine as a treatment for ulcerative colitis. Expert Opin Drug Saf 2007;6:99–107.10.1517/14740338.6.2.99Search in Google Scholar PubMed

53. Rutgeerts P, Vermeire S, Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut 2007;56:453–5.10.1136/gut.2005.088732Search in Google Scholar PubMed PubMed Central

54. D’Arienzo A, Manguso F, Castiglione GN, Vicinanza G, Scaglione G, Bennato R, et al. Beclomethasone dipropionate (3 mg) enemas combined with oral 5-ASA (2.4 g) in the treatment of ulcerative colitis not responsive to oral 5-ASA alone. Ital J Gastroenterol Hepatol 1998;30:254–7.Search in Google Scholar

55. Mulder CJ, Fockens P, Meijer JW, van der Heide H, Wiltink EH, Tytgat GN. Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis. Eur J Gastroenterol Hepatol 1996;8:549–53.10.1097/00042737-199606000-00010Search in Google Scholar PubMed

56. Lofberg R, Danielsson A, Suhr O, Nilsson A, Schiöler R, Nyberg A, et al. Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis. Gastroenterology 1996;110:1713–8.10.1053/gast.1996.v110.pm8964395Search in Google Scholar PubMed

57. Baron JH, Connell AM, Kanaghinis TG, Lennard-Jones JE, Jones AF. Out-patient treatment of ulcerative colitis. Comparison between three doses of oral prednisone. Br Med J 1962;2:441–3.10.1136/bmj.2.5302.441Search in Google Scholar PubMed PubMed Central

58. Möllmann H, Rohdewald P, Barth J, Möllmann C, Verho M, Derendorf H. Comparative pharmacokinetics of methylprednisolone phosphate and hemisuccinate in high doses. Pharm Res 1988;5:509–13.10.1023/A:1015921408870Search in Google Scholar

59. Tromm A, Möllmann H, Barth J, Hochhaus G, Krieg M, Bigalke C, et al. Pharmacokinetics and rectal bioavailability of hydrocortisone acetate after single and multiple administration in healthy subjects and patients. J Clin Pharmacol 2001;41:536–41.10.1177/00912700122010410Search in Google Scholar PubMed

60. Buchman AL. Side effects of corticosteroid therapy. J Clin Gastroenterol 2001;33:289–94.10.1097/00004836-200110000-00006Search in Google Scholar PubMed

61. Rosenberg W, Ireland A, Jewell DP. High-dose methylprednisolone in the treatment of active ulcerative colitis. J Clin Gastroenterol 1990;12:40–1.10.1097/00004836-199002000-00011Search in Google Scholar PubMed

62. Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol 2007;5:103–10.10.1016/j.cgh.2006.09.033Search in Google Scholar PubMed

63. Randall J, Singh B, Warren BF, Travis SP, Mortensen NJ, George BD. Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications. Br J Surg 2010;97:404–9.10.1002/bjs.6874Search in Google Scholar PubMed

64. Roberts SE, Williams JG, Yeates D, Goldacre MJ. Mortality in patients with and without colectomy admitted to hospital for ulcerative colitis and Crohn’s disease: record linkage studies. Br Med J 2007;335:1033–6.10.1136/bmj.39345.714039.55Search in Google Scholar PubMed PubMed Central

65. Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porro G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006;55:47–53.10.1136/gut.2005.068809Search in Google Scholar PubMed PubMed Central

66. Cara CJ, Pena AS, Sans M, Rodrigo L, Guerrero-Esteo M, Hinojosa J. Reviewing the mechanism of action of thiopurine drugs: towards a new paradigm in clinical practice. Med Sci Monit 2004;10:RA247–54.Search in Google Scholar

67. Van Asseldonk DP, Seinen ML, de Boer NK, van Bodegraven AA, Mulder CJ. Hepatotoxicity associated with 6-methyl mercaptopurine formation during azathioprine and 6-mercaptopurine therapy does not occur on the short-term during 6-thioguanine therapy in IBD treatment. J Crohns Colitis 2012;6:95–101.10.1016/j.crohns.2011.07.009Search in Google Scholar PubMed

68. Bradford K, Shih DQ. Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease. World J Gastroenterol 2011;17:4166–73.10.3748/wjg.v17.i37.4166Search in Google Scholar PubMed PubMed Central

69. Teml A, Schaeffeler E, Herrlinger KR, Klotz U, Schwab M. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. Clin Pharmacokinet 2007;46:187–208.10.2165/00003088-200746030-00001Search in Google Scholar

70. Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Théorêt Y, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000;118:705–13.10.1016/S0016-5085(00)70140-5Search in Google Scholar

71. Uchiyama K, Takagi T, Iwamoto Y, Kondo N, Okayama T, Yoshida N, et al. New genetic biomarkers predicting azathioprine blood concentrations in combination therapy with 5-aminosalicylic acid. PLoS One 2014;9:e95080.10.1371/journal.pone.0095080Search in Google Scholar

72. Lee KM, Kim YS, Seo GS, Kim TO, Yang S-K. Use of thiopurines in inflammatory bowel disease: a consensus statement by the Korean Association for the Study of Intestinal Diseases (KASID). Intest Res 2015;13:193–207.10.5217/ir.2015.13.3.193Search in Google Scholar

73. Ng SC, Chan FK, Sung JJ. Review article: the role of non-biological drugs in refractory inflammatory bowel disease. Aliment Pharmacol Ther 2011;33:417–27.10.1111/j.1365-2036.2010.04541.xSearch in Google Scholar

74. Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysis. Clin Gastroenterol Hepatol 2009;7:874–81.10.1016/j.cgh.2009.01.004Search in Google Scholar

75. Matsuda S, Koyasu S. Mechanism of action of cyclosporine. Immunopharmacology 2000;47:119–25.10.1016/S0162-3109(00)00192-2Search in Google Scholar

76. Choc MG. Bioavailability and pharmacokinetics of cyclosporine formulations: Neoral vs Sandimmune. Int J Dermatol 1997;36:1–6.10.1046/j.1365-4362.36.s1.2.xSearch in Google Scholar PubMed

77. Tedesco D, Haragsim L. Cyclosporine: a review. J Transplant 2012;2012:230386.10.1155/2012/230386Search in Google Scholar PubMed PubMed Central

78. Loftus CG, Loftus EV, Sandborn WJ. Cyclosporin for refractory ulcerative colitis. Gut 2003;52:172–3.10.1136/gut.52.2.172Search in Google Scholar PubMed PubMed Central

79. Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol 1999; 94:1587–92.10.1111/j.1572-0241.1999.01149.xSearch in Google Scholar

80. Walch A, Meshkat M, Vogelsang H, Novacek G, Dejaco C, Angelberger S, et al. Long-term outcome in patients with ulcerative colitis treated with intravenous cyclosporine A is determined by previous exposure to thiopurines. J Crohns Colitis 2010;4:398–404.10.1016/j.crohns.2010.01.001Search in Google Scholar

81. Sternthal MB, Murphy SJ, George J, Kornbluth A, Lichtiger S, Present DH. Adverse events associated with the use of cyclosporine in patients with inflammatory bowel disease. Am J Gastroenterol 2008;103:937–43.10.1111/j.1572-0241.2007.01718.xSearch in Google Scholar

82. Van Assche G, D’Haens G, Noman M, Vermeire S, Hiele M, Asnong K, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003;125:1025–31.10.1016/S0016-5085(03)01214-9Search in Google Scholar

83. Matsuoka K, Saito E, Fujii T, Takenaka K, Kimura M, Nagahori M, et al. Tacrolimus for the treatment of ulcerative colitis. Intest Res 2015;13:219–26.10.5217/ir.2015.13.3.219Search in Google Scholar PubMed PubMed Central

84. Ogata H, Matsui T, Nakamura M, Iida M, Takazoe M, Suzuki Y, et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006;55:1255–62.10.1136/gut.2005.081794Search in Google Scholar PubMed PubMed Central

85. Yamamoto S, Nakase H, Mikami S, Inoue S, Yoshino T, Takeda Y, et al. Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. Aliment Pharmacol Ther 2008;28:589–97.10.1111/j.1365-2036.2008.03764.xSearch in Google Scholar PubMed

86. Herrlinger KR, Koc H, Winter S, Teml A, Stange EF, Fellermann K, et al. ABCB1 single-nucleotide polymorphisms determine tacrolimus response in patients with ulcerative colitis. Clin Pharmacol Ther 2011;89:422–8.10.1038/clpt.2010.348Search in Google Scholar PubMed

87. Inoue T, Murano M, Narabayashi K, Okada T, Nouda S, Ishida K, et al. The efficacy of oral tacrolimus in patients with moderate/severe ulcerative colitis not receiving concomitant corticosteroid therapy. Intern Med 2013;52:15–20.10.2169/internalmedicine.52.8555Search in Google Scholar PubMed

88. Kawakami K, Inoue T, Murano M, Narabayashi K, Nouda S, Ishida K, et al. Effects of oral tacrolimus as a rapid induction therapy in ulcerative colitis. World J Gastroenterol 2015;21:1880–6.10.3748/wjg.v21.i6.1880Search in Google Scholar PubMed PubMed Central

89. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462–76.10.1056/NEJMoa050516Search in Google Scholar PubMed

90. Reinisch W, Sandborn WJ, Hommes DW, D’Haens G, Hanauer S, Schreiber S, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011;60:780–7.10.1136/gut.2010.221127Search in Google Scholar PubMed

91. Sandborn WJ, van Assche G, Reinisch W, Colombel JF, D’Haens G, Wolf DC, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012;142:257–65.10.1053/j.gastro.2011.10.032Search in Google Scholar PubMed

92. Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014;146:85–95.10.1053/j.gastro.2013.05.048Search in Google Scholar PubMed

93. Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014;146:96–109.10.1053/j.gastro.2013.06.010Search in Google Scholar PubMed

94. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699–710.10.1056/NEJMoa1215734Search in Google Scholar PubMed

95. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008;117:244–79.10.1016/j.pharmthera.2007.10.001Search in Google Scholar PubMed

96. Mease PJ. Adalimumab in the treatment of arthritis. Ther Clin Risk Manag 2007;3:133–48.10.2147/tcrm.2007.3.1.133Search in Google Scholar PubMed PubMed Central

97. Ordás I, Mould DR, Feagan BG, Sandborn WJ. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther 2012;91:635–46.10.1038/clpt.2011.328Search in Google Scholar PubMed

98. Zhou H, Jang H, Fleischmann RM, Bouman-Thio E, Xu Z, Marini JC, et al. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol 2007;47:383–96.10.1177/0091270006298188Search in Google Scholar PubMed

99. Tursi A, Allegretta L, Buccianti N, Della Valle N, Elisei W, Forti G, et al. Effectiveness and safety of golimumab in treating outpatient ulcerative colitis: a real-life prospective, multicentre, observational study in primary inflammatory bowel disease centers. J Gastrointestin Liver Dis 2017;26:239–44.10.15403/jgld.2014.1121.263.trsSearch in Google Scholar PubMed

100. Gilroy L, Allen PB. Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn’s disease? Clin Exp Gastroenterol 2014;7:163–72.10.2147/CEG.S45261Search in Google Scholar PubMed PubMed Central

101. Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D’Haens G, et al. The safety of vedolizumab for ulcerative colitis and crohn’s disease. Gut 2017;66:839–51.10.1136/gutjnl-2015-311079Search in Google Scholar PubMed PubMed Central

102. McLean L, Shea-Donohue T, Cross R. Vedolizumab for the treatment of ulcerative colitis and Crohn’s disease. Immunotherapy 2012;4:883–98.10.2217/imt.12.85Search in Google Scholar PubMed PubMed Central

103. Gorden FH, Hamilton MI, Donoghue S, Greenlees C, Palmer T, Rowley-Jones D, et al. A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4integrin. Aliment Pharmacol Ther 2002;16:699–705.10.1046/j.1365-2036.2002.01205.xSearch in Google Scholar PubMed

104. Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012;366:1870–80.10.1056/NEJMoa1107829Search in Google Scholar PubMed

105. Vermeire S, Ghosh S, Panes J, Dahlerup JF, Luegering A, Sirotiakova J, et al. The mucosal addressin cell adhesion molecule antibody PF-00547659 in ulcerative colitis: a randomised study. Gut 2011;60:1068–75.10.1136/gut.2010.226548Search in Google Scholar PubMed

106. Sandborn WJ, Ghosh S, Panes J, Vranic I, Su C. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012;367:616–24.10.1056/NEJMoa1112168Search in Google Scholar PubMed

107. https://clinicaltrials.gov/ct2/show/NCT01671956?term=bertilimumab&rank=1, accessed on 12 December 2015.Search in Google Scholar

108. Herrlinger KR, Diculescu M, Fellermann K, Hartmann H, Howaldt S, Nikolov R. Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: the ENTRANCE study. J Crohns Colitis 2013;7:636–43.10.1016/j.crohns.2012.09.016Search in Google Scholar PubMed

109. Brasseit J, Kwong Chung CK, Noti M, Zysset D, Hoheisel-Dickgreber N, Genitsch V, et al. Divergent role of interferon-γ and innate lymphoid cells in innate and adaptive immune cell-mediated intestinal inflammation. Front Immuno 2018;9:23.10.3389/fimmu.2018.00023Search in Google Scholar PubMed PubMed Central

110. Danese S, Rudziński J, Brandt W, Dupas JL, Peyrin-Biroulet L. Tralokinumabfor moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study. Gut 2015;64:243–9.10.1136/gutjnl-2014-308004Search in Google Scholar PubMed